FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma.
Antonin VaryLoïc LebellecFrédéric Di FioreNicolas PenelClaire CheymolEmilia RadFarid El HajbiAstrid LièvreJulien EdelineAndré Michel BimbaiMarie-Cécile Le DeleyAnthony TurpinPublished in: Therapeutic advances in medical oncology (2021)
Pragmatic dose adjustments of FOLFIRINOX should be made by oncologists without considering a loss of effect.